Your browser doesn't support javascript.
loading
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Blauvelt, Andrew; Kimball, Alexa B; Augustin, Matthias; Okubo, Yukari; Witte, Michael M; Capriles, Claudia Rodriguez; Sontag, Angelina; Arora, Vipin; Osuntokun, Olawale; Strober, Bruce.
Afiliación
  • Blauvelt A; Oregon Medical Research Center, Portland, OR, USA.
  • Kimball AB; Department of Dermatology, Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Augustin M; Health Care Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Okubo Y; Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
  • Witte MM; Eli Lilly and Company, Indianapolis, IN, USA.
  • Capriles CR; Eli Lilly and Company, Indianapolis, IN, USA.
  • Sontag A; Eli Lilly and Company, Indianapolis, IN, USA.
  • Arora V; Eli Lilly and Company, Indianapolis, IN, USA.
  • Osuntokun O; Eli Lilly and Company, Indianapolis, IN, USA.
  • Strober B; Yale University, New Haven, CT, USA.
Br J Dermatol ; 187(6): 866-877, 2022 12.
Article en En | MEDLINE | ID: mdl-35791755
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Br J Dermatol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Br J Dermatol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos